8. PRO FORMA FINANCIAL INFORMATION (UNAUDITED)

3 Months Ended

Dec. 31, 2018

Pro Forma Financial Information

PRO FORMA FINANCIAL INFORMATION (UNAUDITED)

The following unaudited pro-forma data summarizes the results of operations for the three months ended December 31, 2018 and 2017, as if the Mergers with Cure Based Development had been completed on October 1, 2017. The pro-forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the Mergers had taken place on October 1, 2017.

	Three Months Ended December 31, 2018			Three Months Ended December 31, 2017
Net revenues	$	4,408,505		$	688,110
Operating income (loss)	$	(1,474,673	)	$	(1,456,125	)
Net loss per share – basic and fully diluted	$	(0.06	)	$	(0.06	)

For the per share calculation, it is being assumed that the shares to be issued contractually under the Merger Agreement, upon shareholder approval, have been issued. This would account for an additional 6,500,000 shares issued directly to the members of Cure Based Development and another 8,750,000 shares issued which would have a voting proxy and leak out on voting rights over a 5 year period.